EDENBRIDGE PHARMS
SpecialtyEDENBRIDGE PHARMS is a specialty pharmaceutical company focused on Cardiovascular. Key products include ZUBSOLV.
EDENBRIDGE PHARMS's Key Drugs
EDENBRIDGE PHARMS's core commercial portfolio centers on ZUBSOLV, YARGESA, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
EDENBRIDGE PHARMS's Recent FDA Approvals
New NDA/BLA approvals for EDENBRIDGE PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
EDENBRIDGE PHARMS's Therapeutic Areas
EDENBRIDGE PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EDENBRIDGE PHARMS's Top Competitors
EDENBRIDGE PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EDENBRIDGE PHARMS Pipeline Snapshot
Active clinical trials for EDENBRIDGE PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZUBSOLV leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (1)
Company Info
- First Approval
- 2013-07-03
- Latest
- 2026-04-15
- Applications
- 13